Martin Eatock - Concepedia

Author

Martin Eatock

Also Known As

Eatock, Martin, M Eatock, M M Eatock, M. Eatock, M. M. Eatock, M.M. Eatock, Martin Eatock, Martin M Eatock, Martin M. Eatock, Martin McKinlay Eatock

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

University of Ulster Belfast City Hospital Queen's University Belfast Beatson West of Scotland Cancer Centre Cancer Research UK

About

Martin Eatock is an author at University of Ulster specializing in medicine, radiation oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	1.7K
2	Health Sciences	4	4	152
3	Biochemistry	2	2	46
4	Engineering	1	1	34
5	Biomedical Engineering	1	1	15

Martin Eatock

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, The Lancet UrologySurgical OncologyGastrointestinal OncologyMedicineBiliary Cancer	2023	891
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer David Cunningham, Ian Chau, Deborah Stocken, Journal of Clinical Oncology	2009	816
A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours Ruth Plummer, Richard H. Wilson, Hilary Calvert, British Journal of Cancer	2011	378
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial Gary Middleton, Paul Silcocks, Trevor F. Cox, The Lancet Oncology Pancreatic CancerMedicineImmunologyMetastatic Pancreatic CancerCancer Treatment	2014	370
A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors Simon Pacey, Richard H. Wilson, Mike Walton, Clinical Cancer Research	2011	189
Capecitabine (Xeloda®) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors Eduardo Díaz‐Rubio, T.R. Jeffry Evans, Josep Tabernero, Annals of Oncology Dose-escalation StudyOncologyMedicinePharmacotherapyAnti-cancer Agent	2002	109
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer Nicola Annels, Victoria Shaw, Rachel F. Gabitass, Cancer Immunology Immunotherapy Pancreatic CancerLow-dose Adjuvant Gm-csfMedicineImmunologyCapecitabine Combination Chemotherapy	2013	91
A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma Robert J. Jones, Robert E. Hawkins, Martin Eatock, Cancer Chemotherapy and Pharmacology OncologyEsophageal CancerGastrointestinal OncologyMedicinePathology	2007	67
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer Martin Eatock, Niall C. Tebbutt, Carolyn Bampton, Annals of Oncology OncologyPhase IiGastrointestinal OncologyEsophageal CancerMedicine	2012	64
Phase I and pharmacokinetic study of NC-6004, a new platinum entity of cisplatin-conjugated polymer forming micelles Richard H. Wilson, Ronda Plummer, Jean‐François Adam, Journal of Clinical Oncology New Platinum EntityEngineeringPolymer-drug ConjugatePolymer SciencePharmacokinetic Study	2008	34

Page 1